<?xml version='1.0' encoding='utf-8'?>
<document id="18449471"><sentence text="The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib."><entity charOffset="138-146" id="DDI-PubMed.18449471.s1.e0" text="imatinib" /></sentence><sentence text="Imatinib is transported by P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP), however, the exact impact of these transporters on absorption, distribution, metabolism and excretion (ADME) of imatinib is not fully understood due to incomplete data"><entity charOffset="0-8" id="DDI-PubMed.18449471.s2.e0" text="Imatinib" /><entity charOffset="206-214" id="DDI-PubMed.18449471.s2.e1" text="imatinib" /><pair ddi="false" e1="DDI-PubMed.18449471.s2.e0" e2="DDI-PubMed.18449471.s2.e0" /><pair ddi="false" e1="DDI-PubMed.18449471.s2.e0" e2="DDI-PubMed.18449471.s2.e1" /></sentence><sentence text=" We have performed a comprehensive ADME study of imatinib given as single agent or in combination with the well known BCRP/P-gp inhibitors, elacridar and pantoprazole, in wild-type and P-gp and/or BCRP knockout mice"><entity charOffset="49-57" id="DDI-PubMed.18449471.s3.e0" text="imatinib" /><entity charOffset="154-166" id="DDI-PubMed.18449471.s3.e1" text="pantoprazole" /><pair ddi="false" e1="DDI-PubMed.18449471.s3.e0" e2="DDI-PubMed.18449471.s3.e0" /><pair ddi="false" e1="DDI-PubMed.18449471.s3.e0" e2="DDI-PubMed.18449471.s3.e1" /></sentence><sentence text=" The absence of P-gp and BCRP together resulted in a significantly higher area under the plasma concentration-time curve (AUC) after i" /><sentence text="v" /><sentence text=" administration, whereas the AUC after oral dosing was unaltered" /><sentence text=" Both elacridar and pantoprazole significantly increased the AUC of orally administered imatinib in wild-type but also in P-gp/BCRP knockout mice"><entity charOffset="20-32" id="DDI-PubMed.18449471.s7.e0" text="pantoprazole" /><entity charOffset="88-96" id="DDI-PubMed.18449471.s7.e1" text="imatinib" /><pair ddi="false" e1="DDI-PubMed.18449471.s7.e0" e2="DDI-PubMed.18449471.s7.e0" /><pair ddi="false" e1="DDI-PubMed.18449471.s7.e0" e2="DDI-PubMed.18449471.s7.e1" /></sentence><sentence text=" This lower clearance was not due to a (further) reduction in biliary excretion" /><sentence text=" Fecal excretion was significantly reduced in P-gp and P-gp/BCRP knockout but not in BCRP knockout mice, whereas the brain penetration was significantly higher in P-gp/BCRP knockout mice compared to single P-gp or BCRP knockout or wild-type mice" /><sentence text=" In conclusion, P-gp and BCRP have only a modest effect on the ADME of imatinib in comparison to metabolic elimination"><entity charOffset="71-79" id="DDI-PubMed.18449471.s10.e0" text="imatinib" /></sentence><sentence text=" P-gp is the most prevalent factor for systemic clearance and limiting the brain penetration" /><sentence text=" The considerable drug-drug interaction observed with elacridar or pantoprazole is only partly mediated by inhibition of P-gp and BCRP and far more by the inhibition of other elimination pathways"><entity charOffset="67-79" id="DDI-PubMed.18449471.s12.e0" text="pantoprazole" /></sentence><sentence text="" /></document>